Floatz logo

Rivaroxaban

TIA

General Hospital of Shenyang Military RegionSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the TIA cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Sichuan Provincial People's Hospital
Phase 4BBB
Plavix
Sichuan Provincial People's Hospital
Phase 4BBB
Ticagrelor
Mazandaran University of Medical Sciences
Phase 3BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Apixaban
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Phase 4BBB

View all 45 →

Same molecule, other indications

Rivaroxaban is also rated in:

atrial fibrillationDormant
BBB
Indicative ·
79 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
thrombotic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →